School of Economic and Management, Nanjing Tech University, Nanjing 211816, China.
Research Center of Big Data Decision-Making and Social Performance Evaluation, Nanjing Tech University, Nanjing 211816, China.
J Healthc Eng. 2020 Feb 14;2020:4109354. doi: 10.1155/2020/4109354. eCollection 2020.
Frequent outbreaks of drug safety incidents pose a massive threat to public health and safety, while the transparency of security risk information in medical enterprises is not optimistic. Therefore, this study uses the analytic network process (Dempster-Shafer method) to construct a transparent comprehensive evaluation model for security risk information in listed pharmaceutical enterprises from the perspective of government supervision and listed pharmaceutical enterprises. On the basis of 59,305 data obtained by 303 enterprises listed in the Chinese biomedical sector, this research conducted an empirical study on the transparency of safety risk information in Chinese listed pharmaceutical enterprises. The current study found that the transparency of security risk information in Chinese listed pharmaceutical enterprises is generally between "general" and "relatively good" and tends to be "relatively good." However, administrative punishment information, adverse drug reaction reporting systems, and production processes need continuous improvement.
药品安全事件频发，对公众健康和安全构成巨大威胁，而医药企业安全风险信息透明度并不乐观。因此，本研究采用网络分析法（Dempster-Shafer 方法），从政府监管和上市医药企业两个角度构建了上市医药企业安全风险信息透明综合评价模型。基于中国生物医药领域 303 家企业获得的 59305 条数据，对中国上市医药企业安全风险信息透明度进行了实证研究。结果表明，中国上市医药企业安全风险信息透明度总体处于“一般”和“相对较好”之间，且有向“相对较好”转变的趋势，但行政处罚信息、药品不良反应报告制度、生产工艺仍需不断完善。
